Anti-EBV核Antigen/EBNA1抗体[E1-2.5] (ab8329)
Key features and details
- Mouse monoclonal [E1-2.5] to EBV Nuclear Antigen/EBNA1
- Suitable for: IHC-P, ICC, ELISA
- Isotype: IgG2b
概述
-
产品名称
Anti-EBV核Antigen/EBNA1抗体[E1-2.5]
参阅全部 EBV Nuclear Antigen/EBNA1 一抗 -
描述
小鼠单克隆抗体[E1-2.5] to EBV核Antigen/EBNA1 -
宿主
Mouse -
特异性
Recognizes repetitive gly-ala region of the nuclear antigen 1 of Epstein Barr virus (EBNA-1). -
经测试应用
适用于: IHC-P, ICC, ELISAmore details -
种属反应性
与反应: Epstein-Barr virus -
免疫原
Synthetic peptide. Corresponding to the repetitive Gly-Ala region of EBNA1.
Database link: P03211 -
常规说明
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. -
存储溶液
pH: 7.40
Preservative: 0.097% Sodium azide
Constituent: PBS -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
E1-2.5 -
同种型
IgG2b -
研究领域
相关产品
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
应用
应用 | Ab评论 | 说明 |
---|---|---|
IHC-P |
Use at an assay dependent concentration. PubMed: 18258188
|
|
ICC |
Use at an assay dependent concentration.
|
|
ELISA |
Use at an assay dependent concentration.
|
说明 |
---|
IHC-P
Use at an assay dependent concentration. PubMed: 18258188 |
ICC
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. |
靶标
-
相关性
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers. -
细胞定位
Nuclear. Free in the nucleoplasm, somewhat associated with the chromatin and hardly, if at all associated with the nuclear matrix. -
数据库链接
- SwissProt: P03211 Epstein-Barr virus
-
别名
- EBNA1 antibody
- EBV nuclear antigen 1 antibody
- Epstein Barr nuclear antigen 1 antibody
see all
数据表及文件
-
SDS download
-
Datasheet download
文献 (9)
ab8329 被引用在 9 文献中.
- Julius P et al. Co-infection and co-localization of Kaposi sarcoma-associated herpesvirus and Epstein-Barr virus in HIV-associated Kaposi sarcoma: a case report. Front Cell Infect Microbiol 13:1270935 (2023). PubMed: 37928187
- Julius P et al. Epstein-Barr Virus, But Not Human Papillomavirus, Is Associated With Preinvasive and Invasive Ocular Surface Squamous Neoplasias in Zambian Patients. Front Oncol 12:864066 (2022). PubMed: 35494029
- Wang H et al. The Hsp70 inhibitor 2-phenylethynesulfonamide inhibits replication and carcinogenicity of Epstein-Barr virus by inhibiting the molecular chaperone function of Hsp70. Cell Death Dis 9:734 (2018). PubMed: 29959331
- Wang C et al. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism. Oncol Rep 37:2109-2120 (2017). PubMed: 28259949
- Ni C et al. In-cell infection: a novel pathway for Epstein-Barr virus infection mediated by cell-in-cell structures. Cell Res 25:785-800 (2015). PubMed: 25916549
- Cardinaud S et al. The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One 5:e8692 (2010). PubMed: 20098683
- Fawzy S et al. Detection of Epstein-Barr virus in breast carcinoma in Egyptian women. Clin Biochem 41:486-92 (2008). IHC-P . PubMed: 18258188
- Haque T et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110:1123-31 (2007). IHC-P . PubMed: 17468341
- McClain MT et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 54:360-8 (2006). PubMed: 16385527